Skip to main content

Table 7 Site of recurrence and the cause of death in premenopausal breast cancer patients treated with tamoxifen or toremifene

From: A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study

  Tamoxifen (n = 240) Toremifene (n = 212)
Recurrences 23(9.6%) 6(2.8%) 2
 Logoregional 14  
  Distant 15 4
  Lymph nodes or  other soft tissues 3 2
  Bone 8 2
 Liver 4 1
  Contralateral  breast cancer 1 0
 Brain 2 0
  Lung 4 0
Deaths 5(2.1%) 0(0%)
  Breast cancer 4 0
  Other reasons 1 0
  1. In the tamoxifen group, there were 12 patients with multiple site of recurrence, of which 7 had more than one site where distant metastases were detected, 5 had concurrent locoregional and one or more sites of distant recurrence. In the toremifene group, there was 1 patient who had concomitant bone and liver metastases.